U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H20ClN3O3S
Molecular Weight 369.866
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIPAMIDE

SMILES

[H][C@@]12CN(C[C@]1([H])[C@@H]3CC[C@H]2C3)NC(=O)C4=CC=C(Cl)C(=C4)S(N)(=O)=O

InChI

InChIKey=UHLOVGKIEARANS-NIFPGPBJSA-N
InChI=1S/C16H20ClN3O3S/c17-14-4-3-11(6-15(14)24(18,22)23)16(21)19-20-7-12-9-1-2-10(5-9)13(12)8-20/h3-4,6,9-10,12-13H,1-2,5,7-8H2,(H,19,21)(H2,18,22,23)/t9-,10+,12-,13+

HIDE SMILES / InChI
Molecular Formula C16H20ClN3O3S
Molecular Weight 369.866
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/6861441 and http://www.genome.jp/dbget-bin/www_bget?D01895

Tripamide is a new diuretic derived from a sulfonamide nucleus that has both antihypertensive and natriuretic properties. It is Na-K-Cl cotransporter inhibitor. The antihypertensive mechanism of tripamide is considered to be based on a mild saluretic action and a peripheral vasodilation action. Tripamide is an ingredient of Normonal in Japan, indicated for the treatment of essential hypertension.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
NORMONAL

Approved Use

Essential hypertension

Launch Date

1982
PubMed

PubMed

TitleDatePubMed
Effects of N-(4-azo-endo-tricyclo[5.2.1.0.(2.6)]-decan-4-yl)-4-chloro-3-sulfamoylbenzamide (E614; tripamide) on vascular smooth muscles.
1982
Sites of action of tripamide.
1983 Jul
Antihypertensive and biochemical dose-response study of tripamide.
1986 Sep
Patents

Patents

7927613
118

Sample Use Guides

In Vivo Use Guide
The usual adult dosage for oral use is 15 mg of tripamide (one tablet) once to twice daily after breakfast or after breakfast and lunch
Route of Administration: Oral
In Vitro Use Guide
In the guniea-pig mesenteric artery, Tripamide (less than 10(-6) g/ml) suppressed the spike evoked by outward current pulses in the presence of 3-5 mM TEA.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:05:17 GMT 2023
Edited
by admin
on Fri Dec 15 15:05:17 GMT 2023
Record UNII
G36A0E9CVT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRIPAMIDE
INN   JAN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
BENZAMIDE, 3-(AMINOSULFONYL)-4-CHLORO-N-(OCTAHYDRO-4,7-METHANO-2H-ISOINDOL-2-YL)-, (3A.ALPHA.,4.ALPHA.,7.ALPHA.,7A.ALPHA.)-
Common Name English
4-Chloro-N-(endo-hexahydro-4,7-methanoisoindolin-2-yl)-3-sulfamoylbenzamide
Common Name English
NORMONAL
Brand Name English
TRIPAMIDE [JAN]
Common Name English
ADR-033
Code English
E-614
Code English
TRIPAMIDE [MI]
Common Name English
TRIPAMIDE [USAN]
Common Name English
TRIPAMIDE [MART.]
Common Name English
tripamide [INN]
Common Name English
Tripamide [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C448
Created by admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
Code System Code Type Description
MERCK INDEX
m11179
Created by admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL2104484
Created by admin on Fri Dec 15 15:05:17 GMT 2023 , Edited by admin on Fri Dec 15 15:05:17 GMT 2023
PRIMARY
DRUG CENTRAL
2760
Created by admin on Fri Dec 15 15:05:17 GMT 2023 , Edited by admin on Fri Dec 15 15:05:17 GMT 2023
PRIMARY
CAS
73803-48-2
Created by admin on Fri Dec 15 15:05:17 GMT 2023 , Edited by admin on Fri Dec 15 15:05:17 GMT 2023
PRIMARY
MESH
C031282
Created by admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
PRIMARY
USAN
T-12
Created by admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
PRIMARY
FDA UNII
G36A0E9CVT
Created by admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
PRIMARY
PUBCHEM
5282210
Created by admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
PRIMARY
SMS_ID
100000076930
Created by admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
PRIMARY
WIKIPEDIA
TRIPAMIDE
Created by admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
PRIMARY
NCI_THESAURUS
C152751
Created by admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
PRIMARY
INN
4936
Created by admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
PRIMARY
EVMPD
SUB11320MIG
Created by admin on Fri Dec 15 15:05:17 GMT 2023 , Edited by admin on Fri Dec 15 15:05:17 GMT 2023
PRIMARY
EPA CompTox
DTXSID2057817
Created by admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
PRIMARY
Related Record Type Details
Structure of TRIPAMIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966